Asset profile
WD-1603
Small molecule
Evidence outlook · lead readout
NCT05036473 · Parkinson Disease
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
NCT05036473: This randomized, double-blind, placebo-controlled Phase 2 trial in early Parkinson's disease enrolled only 40 patients across three dose groups and placebo. All three doses of WD-1603 produced a statistically significant improvement in combined motor and daily-living function scores versus placebo at 27 days, with the largest effect at the highest dose (p=0.0003), but the very small sample size means these results need confirmation in a larger trial.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
69 competitors in this universe: 9 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 39 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| WD-1603: this drug | Phase 2 | Small molecule | dopamine precursor | ||
| Crexont (IPX203) | Approved | Small molecule | dopamine precursor | ||
| Foslevodopa / Foscarbidopa (Vyalev) | Approved | Small molecule | dopamine precursor | ||
| Inbrija (CVT-301) | Approved | Small molecule | dopamine precursor | ||
| Levodopa-Carbidopa Intestinal Gel (Duopa) | Approved | Small molecule | dopamine precursor | ||
| Parcopa | Approved | Small molecule | dopamine precursor | ||
| Rytary (IPX066) | Approved | Small molecule | dopamine precursor | ||
| ND0612 | Phase 3 | Small molecule | dopamine precursor | ||
| TR-012001 | Phase 2 | Small molecule | dopamine precursor | ||
| Melevodopa / Carbidopa (Sirio) | Phase 1/2 | Small molecule | dopamine precursor | ||
| Amantadine ER (Gocovri / ADS-5102) | Approved | Small molecule | NMDA receptor | ||
| Apomorphine (Apokyn) | Approved | Small molecule | dopamine | ||
| Apomorphine Sublingual Film (Kynmobi) | Approved | Small molecule | dopamine | ||
| Entacapone (Comtess) | Approved | Small molecule | COMT | ||
| Istradefylline (Nourianz) | Approved | Small molecule | adenosine A2A | ||
| Opicapone (Ongentys) | Approved | Small molecule | COMT, PDE4 |
…and 54 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
3 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.